Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
The Natural Products, the Immune Diseases and the Cancers
share announcement

The Natural Products, the Immune Diseases and the Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 1725

Special Issue Editor

Dr. Chi Chien Lin

E-Mail Website
Guest Editor
Institute of Biomedical Sciences (IBS), College of Life Sciences, National Chung-Hsing University, Taichung, Taiwan
Interests: Immuno-oncology; autoimmunity; bioactive natural/organic synthetic pharmaceuticals

Special Issue Information

Dear Colleagues,

The immune system consists of a matrix of cells, signal pathways and tissue reactivity. It maintains homeostasis in the living and aberrant function, either over- or down-regulated condition, can cause various disorders and jeopardize the hosts. Generally, it not only protects us from intruding pathogens, but is also essential in inherited or acquired immune diseases. In some special occasions, when an overactive immune system is against one’s own tissues, autoimmune diseases occur and they can exist in any organs of the body. Aside from these, a sustained inflammatory process is also deemed as one of the features in cancerous development. Although the pathophysiologies underlying different cancers are distinct, the immune system is often observed to be altered. Herein, immune microenvironments have emerged as one of the most prevalent topics in cancer research nowadays, either as predictive markers or therapeutic targets.

Immune-related diseases are sometimes serious and can cause everlasting destruction. However, current therapeutic choices are few and with limited efficacy from time to time. Our environment is provided with plentiful bioactive sources, allowing us to extract compounds for medication. These materials embrace the enhanced or suppressive abilities in modulating immunity, and there are chances that scientists may further synthesize them with semisynthetic or total synthetic techniques. In this way, it is crucial to understand and illustrate the detailed relationship between natural products and their immunomodulatory capacities. As mentioned above, the future of nature products is promising. They can serve as the alternate therapeutic choices and immune-related diseases, as well as cancers, can be benefited. In this regard, we would like to invite researchers worldwide to submit and share studies regarding, but not limit to, the following topics (Contributions from every corner of the natural products field are welcome, but must be based on concrete, chemically well-defined compounds, such as curcumin):     

  • Introducing immunomodulatory natural products from the environment, such as animals and plants.
  • Discussing the mechanism of natural products in certain immunomodulatory pathways of immune-related diseases or cancers.
  • Enlightening how natural products will be applied in immune-related diseases or cancers.
  • Finding how immunomodulatory natural products inhibit the intruding pathogens or cancers.
  • Discussing how to refine the production of natural products applied in immune-related diseases or cancers.
  • Preclinical and clinical studies regarding the safety and/or effectiveness of natural products in diseases or cancers based on immune system.
  • Review articles regarding the interaction between natural products and immune system or cancers.

Dr. Chi Chien Lin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • humans
  • animals
  • chemistry
  • pharmacology
  • anti-Inflammatory agents/pharmacology mechanisms
  • anti-inflammatory agents/isolation and purification
  • immune system diseases/drug therapy
  • immune system diseases/immunology
  • host–pathogen interactions/physiology
  • meta-analysis as topic
  • systematic reviews as topic

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 6049 KiB  
Article
Critical Sites on Ostreolysin Are Responsible for Interaction with Cytoskeletal Proteins
by Nastacia Adler Berke, Antonella Di Pizio, Timothy D. Vaden, Irit Shoval, Ofer Gover, Daniel Waiger, Gili Solomon, Kristina Sepčić and Betty Schwartz
Biomedicines 2022, 10(10), 2442; https://doi.org/10.3390/biomedicines10102442 - 30 Sep 2022
Viewed by 1316
Abstract
We explored the structural features of recombinant ostreolysin A (rOlyA), a protein produced by Pleurotus ostreatus and responsible for binding to α/β-tubulin. We found that rOlyA cell internalization is essential for the induction of adipocyte-associated activity, which is mediated by the interaction of [...] Read more.
We explored the structural features of recombinant ostreolysin A (rOlyA), a protein produced by Pleurotus ostreatus and responsible for binding to α/β-tubulin. We found that rOlyA cell internalization is essential for the induction of adipocyte-associated activity, which is mediated by the interaction of rOlyA and microtubule proteins. We created different point mutations at conserved tryptophan (W) sites in rOlyA and analyzed their biological activity in HIB-1B preadipocytes. We demonstrated that the protein’s cell-internalization ability and the differentiated phenotype induced, such as small lipid-droplet formation and gene expression of mitogenesis activity, were impaired in point-mutated proteins W96A and W28A, where W was converted to alanine (A). We also showed that an rOlyA homologue, OlyA6 complexed with mCherry, cannot bind to β-tubulin and does not induce mitochondrial biosynthesis-associated markers, suggesting that the OlyA6 region masked by mCherry is involved in β-tubulin binding. Protein–protein docking simulations were carried out to investigate the binding mode of rOlyA with β-tubulin. Taken together, we identified functional sites in rOlyA that are essential for its binding to β-tubulin and its adipocyte-associated biological activity. Full article
(This article belongs to the Special Issue The Natural Products, the Immune Diseases and the Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop